

OFFICIALLY LICENSED
BEST OF ASCO[®]
2021 ANNUAL MEETING
Sri Lanka

In collaboration with



SRI LANKA COLLEGE OF
ONCOLOGISTS

SCIENTIFIC AGENDA

Presented by



Message from the President - Sri Lanka College of Oncology

Dear Distinguished Guests and Colleagues,

On behalf of the Sri Lanka College of Oncologists (SLCO), I welcome you with great pleasure to the first ever Best of ASCO, Sri Lanka 2021. scheduled to be hosted between 18th & 19th December 2021 on an interactive, immersive & user-friendly platform.

The SLCO is greatly honored to be associated with Best of ASCO & MCI Group as it is the first time that a conference of such an importance is to be held in Sri Lanka.

ASCO conferences have become a premier platform not only for the presentation of new science but also for unique networking opportunity.

Best of ASCO 2021, Sri Lanka shall showcase stimulating presentations from world renowned speakers from ASCO 2021 that concluded in June this year. The participants will have access to around 40 abstracts which have been chosen for the presentation and discussion. Most of these abstracts will be presented by the original authors themselves whilst the others will be presented by the attending professionals with specific interest on the subject matters.

There are many groundbreaking topics and clinical developments in the field of Oncology. This conference provides the ideal forum to discuss latest findings and how can it improve our daily clinical practices.

I look forward to an inspiring, educational, and enjoyable program, once again I welcome you to this interactive, immersive & first ever virtual Best of ASCO 2021, Sri Lanka.

Thank you for joining us!

Dr. A. J. Hilmi. MD.

President

Sri Lanka College of Oncologist



Message from the Secretary - Sri Lanka College of Oncology

Dear Fraternity Members,

It's a pleasure to welcome you to Best of ASCO Sri Lanka - 2021. The Sri Lanka college of Oncologists & MCI India jointly organized to bring top-ranked and outstanding abstracts from the American society of clinical oncology Conference, June 2021, to Best of ASCO Sri Lanka 2021.

It also brings together all Specialities to enlighten the gathering with eye-opening research and innovative ideas.

Best of ASCO Sri Lanka, 2021 is an excellent opportunity to unveil the pathways available to optimize the quality of life of cancer patients with available novel therapeutic options.

Best of ASCO Sri Lanka, 2021 facilitates the capture of different ideas, views, and concerns in Oncology. Our prime role is to advance the competencies and practice among colleagues in the field of Oncology in this region.



Dr. Sachini Malaviarachchi Rasnayake

Secretary

Sri Lanka College of Oncologist

Organizing Committee



Dr. A. J. Hilmi
MD
President, Sri Lanka College of
Oncologis



Dr. Sachini Rasnayaka
MBBS, MD
Secretary, Sri Lanka College of
Oncologist



Dr. Wasantha Rathnayak
MBBS, MD
Treasurer, Sri Lanka College of
Oncologist

Committee Members



Dr. Skandarajah Thuraiarah
MBBS, MD
Consultant Clinical Oncologist
National Cancer Institute, Sri Lanka



Dr. Janaka Thushan Piyasiri
MBBS, MD
Senior Registrar (Clinical Oncology)
National Cancer Institute, Sri Lanka



Dr. Devinda Jayathilake
MBBS, MD
Consultant Haemato-Oncologist
National Cancer Institute, Sri Lanka



Dr. Ahamed Iqbal
MBBS, MD
Consultant Clinical Oncologist
Teaching Hospital Batticaloa, Sri Lanka



Dr. Nuradh Joseph,
MBBS MD MRCP FRCR
Consultant Clinical Oncologist
Teaching Hospital Batticaloa, Sri Lanka



Dr. N Yoganathan
MBBS, MD
Consultant Clinical Oncologist
National Cancer Institute, Sri Lanka



Dr. Jaliya Jayasekera
MBBS, MD
Consultant Clinical Oncologist
District General Hospital Awissawella,
Sri Lanka



Dr. Sanjeeva Gunasekera
MBBS, MD
Consultant Paediatric Oncologist
National Cancer Institute, Sri Lanka



Dr. J Balawardane
MBBS, MD, FRCP (Eding), FRCP (Lon)
Senior Consultant Medical &
Radiation Oncologist,
Faculty of Allied Health Science,
Kotelawala Defence University, Sri Lanka



Dr. N Jeykumaran
MBBS, MD
Consultant Clinical Oncologist
National Cancer Institute Sri Lanka



Dr. Tirusha Navarathna
MBBS, MD
Consultant Clinical Oncologist
District General Hospital Monaragala,
Sri Lanka



Dr. Chrisanthi Rajasooriyar
MBBS, MD
Consultant Clinical Oncologist
Tellipalai Trail Cancer Hospital, Sri Lanka



Dr. Prasad Abeysinghe **MBBS, MD**
Consultant Clinical Oncologists
National Cancer institute - Sri Lanka

Scientific Programme






The Sri Lanka College of Oncologists

DAY 1 | 18th December 2021 | Saturday

Time	Session Type	Speaker	Title of Presentation
Welcome Address by Hon. President of The Sri Lanka College of Oncologists			
11:00 - 11:30	Session 1 - Breast Cancer - Metastatic Moderator: Dr. Jayantha Balawardane		
11:00 - 11:10	Presentation	 Dr. Cosphiadi Irawan	Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.
11:10 - 11:20	Presentation	 Dr. Binghe Xu	Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.
11:20 - 11:30	Presentation	 Dr. Anne L Loeser	Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC).
Quick Quiz Question			
11:30 - 12:30	Session 2 - Breast Cancer - Local/Regional/Adjuvant Moderator: Dr. Niroshan Atulugama		
11:30 - 11:40	Presentation	 Dr. Tiromi Menaka Rupasinghe	OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.
11:40 - 11:50	Presentation	 Dr. Josephine Lopes Cardozo	Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial.
11:50 - 12:00	Presentation	 Dr. Ahamed Iqbal	Breast Cancer Index (BCI) and Prediction of Benefit from Extended Aromatase Inhibitor (AI) Therapy (tx) in HR+ Breast Cancer: NRG Oncology/NSABP B-42.
12:00 - 12:10	Presentation	 Dr. Vaishnavi	De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR/HER2+ biomarker and survival results.
12:10 - 12:30	Panel Discussion & Q&A Session		
12:30 - 12:50	Exhibition Tour Break		
12:50 - 13:10	Session 3 - Central Nervous System Tumors Moderator: Dr. Janaka Thushan Piyasiri		
12:50 - 13:00	Presentation	 Dr. Buddhini Karunaratne	Long-term results of the GEINO 140 TRIAL: randomizing patients to stop or to continue temozolomide until 12 cycles.
13:00 - 13:10	Presentation	 Dr. Ravindi Miriam	Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas.

13:10 - 14:20

Session 4 - Hematology
Moderator: Dr. Yasintha Ratnayake





13:10 - 13:20	Presentation		Dr. Nilupulee Gunarathna	Safety and efficacy of a novel anti-CD20/CD19 bi-specific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL)
13:20 - 13:30	Presentation		Dr. Pradeep Siriwardana	"Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)."
13:30 - 13:40	Presentation		Dr. P. W. Devinda C. Jayathilake	CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (CHL)
13:40 - 13:50	Presentation		Dr. Buddhika Somawardana	"Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma(MM)."
13:50 - 14:00	Presentation		Dr. K. A. I. Nirmali Karasinghearachchi	MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors

14:00 - 14:20

Panel Discussion & Q&A Session

14:20 - 15:20

Session 5 - Gastrointestinal & Hepatobiliary Cancer
Moderator: Dr. Sanjeeva Gunasekara

14:20 - 14:30	Presentation		Dr. Wulyo Rajabto	Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial.
14:30 - 14:40	Presentation		Dr. Chinthaka Appuhamy	Hepatic arterial infusion chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase 3 trial (The FOHAIC-1 study).
14:40 - 14:50	Presentation		Dr. Kavitha Indranath	Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer.
14:50 - 15:00	Presentation		Dr. Chamila Priyadarshani	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).

15:00 - 15:20

Panel Discussion & Q&A Session



Quick Quiz Question

15:20 - 15:40

Exhibition Tour Break

15:40 - 16:00





Session 6 - Gynecologic Cancer
Moderator: Dr. Lakshan Abeynayake

15:40 - 15:50	Presentation		Dr. Hafizah Zaharah	Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890).
15:50 - 16:00	Presentation		Dr. Linda R. Mileschkin	Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase 3 OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).

16:00 - 17:00

Session 7 - Genitourinary Cancer - Prostate, Testicular and Penile





Moderator: Dr. N. Jeyakumaran

16:00 - 16:10	Presentation		Dr. Nisha Shariff	Final analysis of KEYNOTE-426: Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC).
16:10 - 16:20	Presentation		Dr. Jaliya Jayasekara	A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.
16:20 - 16:30	Presentation		Dr. Nuradh Joseph	Phase 3 study of lutetium-177-PSMA-617 in patients within metastatic castration-resistant prostate cancer (VISION).
16:30 - 16:40	Presentation		Dr. Toni K. Choueiri	Pembrolizumab versus placebo as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase 3 KEYNOTE-564 study.

16:40 - 17:00






Panel Discussion & Q&A Session

DAY 2 | 19th December 2021 | Sunday

Time	Session Type	Speaker	Title of Presentation
Opening Remarks by Secretary of The Sri Lanka Collage of Oncologists			
Session 8 – Head and Neck (Dr.Kanthi Perera) Moderator: Dr. Kanthi Perera			
11:00 - 11:20			
11:00 - 11:10	Presentation	 Dr. Andhika	Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.
11:10 - 11:20	Presentation	 Dr. Tan Chih Kiang	JUPITER-02: Randomized,double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
Quick Quiz Question			
Session 9 – Melanoma/ Sarcoma Moderator: Dr. N. Yoganathan			
11:20 - 11:40			
11:20 - 11:30	Presentation	 Dr. Yasiru Malinda	CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.
11:30 - 11:40	Presentation	 Dr. Dimosthenis Andreou	Treatment delays are associated with an unfavorable outcome in patients with localized Ewing sarcoma: A retrospective analysis of data from the GPOH Euro- E.W.I.N.G.99 trial.
Quick Quiz Question			
11:40 - 12:00			
Exhibition Tour Break			

12:00 - 13:00

Session 10 – Lung Cancer
Moderator: Dr. Praveen Tharanga




12:00 - 12:10	Presentation		Dr. Dhammike Rasnayake	Video-assisted thoracoscopic versus open lobectomy in patients with early-stage lung cancer: One-year results from a randomized controlled trial (VIOLET).
12:10 - 12:20	Presentation		Dr. Chrishanthi Rajasooriyar	Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.
12:20 - 12:30	Presentation		Dr. Dean A. Fennell	A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma
12:30 - 12:40	Presentation		Dr. David Lee	First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMat9LA.
12:40 - 12:50	Presentation		Dr. Tirusha Nawarathne	Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150.

12:50 - 13:10

Panel Discussion & Q&A Session

13:10 - 14:00

Session 11 – Pediatric Oncology
Moderator: Dr. Sachini Rasnayake


13:10 - 13:20	Presentation		Dr. Sanjeeva Gunasekara	Updated outcomes for patients with completely resected pulmonary recurrent osteosarcoma: A report from the Children's Oncology Group.
13:20 - 13:30	Presentation		Dr. Prabani S.Maddumaarachchi	Prognostic Impact of CNS-2 status in T-ALL: a report from the Children's Oncology Group.
13:30 - 13:40	Presentation		Dr. P. H. Sahan Piya Udara	Donor-derived CD7 CAR T cells for T-cell acute lymphoblastic leukemia.

13:40 - 14:00

Panel Discussion & Q&A Session

14:00 - 14:10

Session 12 – Other
Moderator: Dr. A. J. Hilmi

14:00 - 14:10	Presentation		Dr. Noorwati Sutandyo	The comparative effectiveness of direct oral anti-coagulants and low molecular weight heparins for prevention of recurrent venous thromboembolism in cancer: The CANVAS pragmatic randomized trial.
---------------	--------------	---	-----------------------	---

Quick Quiz Question


14:10 onwards

Award Declaration & Valedictory (Dr Sachini Rasnayake)



LEADERBOARD!

How to achieve points on Leaderboard ?




**LEADERBOARD AWARDS TO BE WON
DURING BEST OF ASCO 2021, SRI LANKA**

Sponsored by



Complimentary Registration for :
Best of ASCO 2022 Sri Lanka
Best of ASCO 2022 Malaysia



mci
Tomorrow's People

